检索结果-南通市图书馆

Incidence and management of ziv-aflibercept related toxicities in colorectal cancer

World Journal of Clinical Oncology 2014年第5期5卷 1028-1035页

作者： Muhammad Wasif Saif Valerie Relias Kostas Syrigos Krishna S Gunturu GI Oncology Exp. Therapeutic Tufts Medical Center-Tufts Cancer Center Oncology Unit Third Department of Medicine Athens Medical School Sotiria General Hospital Athens Greece Lahey Clinic Burlington MA 02111 United States

ziv-afilbercept(Zaltrap, ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor(VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG 1. Recently, a randomized, open-label, phase Ⅲ study compared 5-fluorouracil, leucovorin, irinotecan(FOLFIRI)/ziv with FOLFIRI/placebo in patients who had been previously treated with oxaliplatin based chemotherapy for metastatic colon cancer(mC RC). Patients who had received prior bevacizumab therapy were also eligible. This study showed that the addition of ziv improved overall survival with median survival time of 13.5 mo vs 12.06 mo in ziv vs placebo arm. ziv also improved progression free survival from 4.67 mo to 6.9 mo with a response rate of 19.8% in the ziv/FOLFIRI group vs 11.1% in FOLFIRI alone group. This led to the approval of ziv in combination with FOLFIRI in metastatic colon cancer patients treated with prior oxaliplatin regimens. The mostcommon side effects were diarrhea, stomatitis, fatigue, hypertension, weight loss, loss of appetite, abdominal pain, and headache. As the use of ziv has become more widespread in oncology practices, familiarity with the toxicity profile of the drug and the use of practice guidelines for their treatment has become increasing important. This review will address the toxicities noted in trials using ziv for the treatment of mC RC, and will provide recommendations for toxicity management.

关键词： ziv-aflibercept Colon cancer Metastatic Bleeding Hypertension

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Complications of ziv-aflibercept in Choroidal and Retinal Vascular Diseases

引用

Open Journal of Ophthalmology 2023年第2期13卷 199-207页

作者： Hussain Ahmad Khaqan Usman Imtiaz Laraib Hassan Sabah Eric Hasnain Muhammad Bukhsh Hafiz Mubashir Farooqui Ahmad Fauzan Muhammad Usman Zia Department of Ophthalmology Post Graduate Medical Institute Lahore General Hospital Ameer Ud Din Medical College Lahore Pakistan Central Park Teaching Hospital Lahore Pakistan Sindh Institute of Ophthalmology and Visual Sciences Hyderabad Pakistan

Introduction: The modern ophthalmology trends are changing rapidly every day with the introduction of much newer studies and research. Numerous anti-vascular endothelial growth factors (VEGF) are utilized as the mainstay in the treatment of intraocular vascular pathologies. The rationale of this study is to add to the literature regarding the safety and efficacy profile of the ziv-aflibercept as there is insubstantial data in patients with intraocular vascular pathologies being treated with this injection with prime focus on the complications of the injection. Materials and Methods: A prospective observational study was conducted at Opthalmology Department, Lahore General Hospital, Lahore between 14 August 2018 and 23 December 2019. Patients with choroidal and retinal vascular diseases like diabetic macular edema (DME), age-related macular degeneration (AMD) and retinal vein occlusion (RVO) who had no active infection of eye and had no history of myocardial infarction or cerebrovascular accident were added in this study. Results: Best-corrected visual acuity was significantly improved at 4, 8, and 12 weeks as compared to the baseline (p Conclusion: The use of ziv-aflibercept injection via intravitreal route under aseptic conditions for choroidal and retinal vascular diseases is effective as well as safe with mild and treatable ocular side effects.

关键词： ziv-aflibercept Anti VEGF Choroidal Vascular Diseases Retinal Vascular Diseases

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

转移性结肠直肠癌治疗药ziv-aflibercept

引用

药学进展 2012年第8期36卷 384-384页

由赛诺菲-安万特(Sanofi-Aventis)公司开发的ziv-aflibercept(商品名:Zaltrap)于2012年8月3日获美国FDA批准,与FOLFIRI化疗方案(亚叶酸+氟尿嘧啶+伊立替康)联合用于治疗成人结肠直肠

关键词： ziv-aflibercept Zaltrap 结肠直肠癌 FOLFIRI方案

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：